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PCommentary
Genotyping
One Piece of the Puzzle to Personalize Antiplatelet Therapy
Paul A. Gurbel, MD,* Udaya S. Tantry, PHD,* Alan R. Shuldiner, MD,† Dean J. Kereiakes, MD‡
Baltimore, Maryland; and Cincinnati, Ohio
The loss-of-function hepatic cytochrome P450 (CYP) 2C19*2 allele has been associated with reduced clopidogrel
active metabolite generation and higher ex vivo platelet reactivity to adenosine diphosphate. Independently, in
post hoc analyses, CYP2C19*2 has been associated with worse clinical outcomes during clopidogrel therapy.
The controversy surrounding the diminished effectiveness of clopidogrel in poor metabolizers, those having 2
loss-of-function alleles, has been recently highlighted in the “boxed warning” issued by the U.S. Food and Drug
Administration. However, much of the variation in clopidogrel response is not explained by the CYP2C19*2 allele
(the most frequent loss-of-function allele), and other factors, both genetic and nongenetic, are likely to be impor-
tant contributors. High on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is a
well-documented predictor of recurrent ischemic events in the percutaneous coronary intervention population.
While platelet function is dynamic in individual patients because of the influence of variable external factors, the
influence of the CYP2C19*2 allele is intrinsically constant. Thus, it may be reasonable to consider both genotyp-
ing and platelet function measurement to assess ischemic risk and to guide antiplatelet therapy. Prospective
clinical trials to test new algorithms for optimal personalized antiplatelet therapy are needed to provide the evi-
dence base required for the routine adoption of genotyping into clinical practice. (J Am Coll Cardiol 2010;56:
112–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.008c
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sn this issue of the Journal, Damani and Topol (1) propose
outine genotyping alone to personalize dual-antiplatelet
herapy. Here we summarize what we know and what we
hould know before using routine genotyping alone for
ersonalized antiplatelet therapy.
hat We Know
he current “one size fits all” antiplatelet regimens recom-
ended by the American Heart Association, American
ollege of Cardiology, and European Society of Cardiology
uidelines are associated with about 10% recurrent ischemic
vent rates (2). Multiple studies have clearly demonstrated
hat platelets play a major role in the genesis of both
eriprocedural and long-term atherothrombotic events, in-
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ccepted April 12, 2010.luding myocardial infarction and stent thrombosis (2).
denosine diphosphate (ADP) is an important secondary
gonist released in response to other agonists (thromboxane
2, collagen, thrombin, and shear) that amplifies platelet
ctivation and aggregation. Persistent activation of the
lycoprotein IIb/IIIa receptor and subsequent stable throm-
us generation at the site of vessel wall injury is highly
ependent on continuous ADP-mediated P2Y12 receptor
ignaling. Therefore, the addition of the P2Y12 receptor
locker clopidogrel to aspirin has been associated with a
ignificant reduction in major cardiovascular events in high-
isk patients. However, nonresponsiveness and high on-
reatment platelet reactivity (HPR) measured by ex vivo
ssays of platelet function have been overwhelmingly as-
ociated with increased ischemic event occurrence in
lopidogrel-treated patients (2).
Pharmacokinetic studies indicate that clopidogrel is con-
erted into its active metabolite by hepatic cytochrome P450
CYP) isoenzymes in a 2-step oxidation process involving
rimarily CYP2C19, CYP1A2, and CYP2B6 isoenzymes in
he first step and CYP2C19, CYP2C9, CYP2B6, and
YP3A4 isoenzymes in the second step. The active metab-
lite (R130964) covalently binds to the platelet P2Y12
eceptors to irreversibly inhibit ADP-stimulated platelet
ggregation. Both CYP2C19 and CYP3A4 have been
uggested as major isoenzymes involved in the metabolic
ctivation of clopidogrel (3).
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July 6, 2010:112–6 Genotyping and Antiplatelet TherapyMultiple lines of evidence show that clopidogrel response
ariability is due largely to variability in active metabolite
eneration (4). There are at least 25 single-nucleotide
olymorphisms (SNPs) of the gene encoding the CYP2C19
soenzyme (5). The most widely analyzed and most frequent
NPs are CYP2C19*2, a G¡A mutation in exon 5 pro-
ucing an aberrant splice site leading to the complete
bsence of CYP2C19 activity, and *17 (-806CT), a
egulatory region variant that has been associated with
ncreased expression and enzymatic activity. The *2 loss-of-
unction and *17 gain-of-function alleles are in linkage
isequilibrium (D=  1, r2  0.04), resulting in 3 observed
aplotypes and 6 possible diplotypes, which may be grouped
nto 3 enzymatic activity phenotypes (6,7) (Fig. 1).
Recently, variation in ADP-stimulated platelet aggrega-
ion in response to clopidogrel was evaluated in a genome-
ide association study in healthy subjects (6). Remarkably,
cluster of 13 SNPs within and flanking the CYP2C18-
C19-2C9-2C8 cluster on chromosome 10q24 (out of
bout 400,000 SNPs analyzed genome-wide) was strongly
ssociated with clopidogrel response (p  1012 to 107).
urther mapping identified the CYP2C19*2 variant, which
ccounted for most or all of the 10q24 association signal. In
replication study involving patients undergoing percuta-
eous coronary intervention, carriers of the CYP2C19*2
llele had higher cardiovascular event rates compared with
oncarriers (hazard ratio [HR]: 2.42; p  0.02) (6). Can-
idate gene studies also support an important role of
YP2C19 reduced-function alleles in clopidogrel nonre-
ponsiveness and adverse clinical outcomes. In healthy
olunteers, a 32.4% relative reduction (p 0.001) in plasma
xposure to the active clopidogrel metabolite and a relative
eduction of approximately 25% in mean platelet aggrega-
ion (p  0.001) was observed in carriers of at least 1
Figure 1 Linkage Disequilibrium and CYP2C19 Haplotypes
Because of linkage disequilibrium between the hepatic cytochrome P450 (CYP) 2C
variants, only 3 (of 4 possible) haplotypes exist. These 3 haplotypes result in 6 di
ers, and poor metabolizers.YP2C19 reduced-function al-
ele compared with noncarriers
8). Among patients with acute
oronary syndromes undergoing
tenting and treated with clopi-
ogrel in the TRITON–TIMI 38
Trial to Assess Improvement in
herapeutic Outcomes by Opti-
izing Platelet Inhibition With
rasugrel–Thrombolysis In Myo-
ardial Infarction 38) study,
YP2C19 reduced-function al-
ele carriers had a higher rate of
ecurrent ischemic events (HR: 1.53; p  0.01), including
tent thrombosis (HR: 3.09; p  0.02), compared with
oncarriers (8). Similarly, Sibbing et al. (9) demonstrated
hat CYP2C19*2 carriers had a significantly higher cumu-
ative 30-day incidence of stent thrombosis compared with
YP2C19 wild-type homozygotes (HR: 3.81; p  0.007).
n a collaborative meta-analysis of various clinical trials
nvolving 9,684 patients, Mega et al. (10) recently demon-
trated that CYP2C19*2 allele carriers had a higher risk of
ajor adverse clinical event occurrence compared with
oncarriers (HR: 1.61; p  0.001). Similarly, risk was
reater in heterozygotes compared with wild type (HR:
.50; p  0.016) and in homozygotes compared with wild
ype (HR: 1.81; p  0.004) (10).
CYP2C19 genotyping is currently available through a
umber of commercial laboratories. However, the turn-
round time is often on the order of several days. Because a
arge number of events happen within the first several hours
fter percutaneous coronary intervention, for personalized
ntiplatelet therapy to be optimally applied, rapid and
ccurate point-of-care CYP2C19 genotyping will be neces-
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CYP  hepatic cytochrome
P450
HPR  high on-treatment
platelet reactivity
HR  hazard ratio
SNP  single-nucleotide
polymorphism
loss-of-function (slow metabolizer) and *17 gain-of-function (fast metabolizer)
s, which define 3 main phenotypes: extensive metabolizers, normal metaboliz-19*2
plotype
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Genotyping and Antiplatelet Therapy July 6, 2010:112–6ary. Currently, these assays are used predominantly for
esearch purposes and include the AmpliChip Cyp450 test
Roche Diagnostics GmbH, Mannheim, Germany), Veri-
ene (Nanosphere, Inc., Northbrook, Illinois), and Infinity
AutoGenomics, Inc., Carlsbad, California). These tests can
e performed on small amounts of whole blood with a
urnaround time of about 3 to 8 h.
hat We Should Know
lthough Damani and Topol (1) refer to “overwhelming
vidence” presented in support of routine, widespread geno-
yping, as yet, there has not been a single, adequately-
owered prospective trial with clinical end points performed
o support this premise. It is hypothesized that the *2 allele
onfers its risk by affecting the pharmacodynamic response
o clopidogrel (4). However, no single study has demon-
trated a conclusive link between the presence of a loss-of-
unction genetic polymorphism, suboptimal clopidogrel ac-
ive metabolite generation (pharmacokinetic measurement),
ecreased clopidogrel responsiveness (pharmacodynamic
easurement), and adverse clinical outcomes.
While most studies show a gene-dose effect, in which
YP2C19*2 homozygotes (approximately 3% to 4% of the
eneral U.S. population) have the worst clopidogrel re-
ponse and heterozygotes (25% to 30% of the general U.S.
opulation) have intermediate responses between wild-type
nd *2 homozygotes, a study by Simon et al. (11) suggested
hat increased risk is limited only to the *2 homozygotes.
YP2C19*2 heterozygotes have 1 normal CYP2C19 allele
nd maintain partial enzymatic activity, while CYP2C19*2
omozygotes have little or no enzymatic activity (4). Thus,
he argument for genotyping may be more persuasive in the
ase of homozygotes. However, it is unclear how future
ersonalized antiplatelet regimens may differ between those
arboring 1 versus 2 CYP2C19*2 alleles.
Because the heritability of clopidogrel response is approx-
mately 70%, and the CYP2C19*2 genotype accounts for
nly about 12% of clopidogrel response variability (not 50%,
s suggested by Damani and Topol [1]), the majority of
actors, both genetic and nongenetic, influencing clopi-
ogrel response variability remain unexplained (6). It is
ikely that several (even many) additional gene variants, both
ommon and rare, exist that once discovered will add to the
redictive value of a panel of genetic markers that will
nclude the CYP2C19 genotype. We recently demonstrated
hat the sensitivity of the *2 carrier state for detecting HPR
as only 56% (7). Determination of diplotype status may
etter identify patients with HPR and associated ischemic
isk.
Sibbing et al. (12) demonstrated that CYCP2C19*17
llele carriers had significantly lower ADP-induced platelet
ggregation (p  0.039) and a higher risk for bleeding
uring clopidogrel treatment compared to wild-type carriers
p  0.01). However, platelet function in patients with
leeding was not reported. Whether the CYP2C19*17 allele effects cardiovascular events is less certain. The independent
ffect of *17 on platelet reactivity during clopidogrel therapy
emains unclear (7). Similarly, very little is known about the
ess common loss-of-function variants (e.g., *3, *4, *5, *6, *7,
8). Greater knowledge of whether these variants (and the
iplotypes they produce) affect clopidogrel response will also
e critical to optimizing personalized antiplatelet therapy
lgorithms. Recently, the TT (vs. CT or CC) genotype at
s1045642 of the ABCB1 gene, which encodes a transporter
hat modulates clopidogrel absorption, has been shown to
e associated with clopidogrel response variability by influ-
ncing clopidogrel absorption and also with worse clinical
utcome (11,13).
In addition to genetics, functional variability in the P450
soenzyme activity that is influenced by drug–drug interac-
ions also contributes to the clopidogrel response variability.
he coadministration of clopidogrel with proton pump
nhibitors, lipophilic statins, calcium-channel blockers, caf-
eine, St. John’s wort, smoking, and warfarin, which are
etabolized by the CYP2C19, CYP3A4, CYP1A2, and
YP2C9 isoenzymes, has been shown to influence the
esponse to clopidogrel (4,14). How these exogenous mod-
fiers of cytochrome P450 function interact with endoge-
ous genetic modulators of cytochrome P450 function is not
nown. Furthermore, clopidogrel response may vary with
he presence of diabetes as well as the level of glucose
ontrol (15) and body mass index (16). Among subjects with
iabetes mellitus, clopidogrel response was significantly
iminished in the presence of an elevated serum fibrinogen
evel (17). Although the consequences of these interactions
ith respect to ischemic event occurrence remain contro-
ersial, it is reasonable to consider incorporating these
actors into personalized antiplatelet algorithms as well.
Numerous translational research studies have correlated
x vivo measures of platelet function with ischemic event
ccurrence using multiple P2Y12 receptor reactivity assays.
recent consensus has been reached on the definition of
PR to ADP determined by receiver-operating character-
stic curve analyses. These cut points of HPR have been
ssociated with adverse ischemic event occurrence, includ-
ng stent thrombosis: 1) platelet reactivity index 50% by
asodilator-stimulated phosphoprotein phosphorylation
nalysis; 2) platelet reaction units 235 by VerifyNow
2Y12 assay (Accumetrics, Inc., San Diego, California);
) maximal platelet aggregation 46% in response to
mol/l ADP; and 4) aggregation units over time468 (in
esponse to ADP) by Multiplate analyzer (Dynabyte Infor-
ationssysteme GmbH, Munich, Germany) (18). A recent
tudy with clinical follow-up identified 3 tests of on-
reatment platelet reactivity—light transmission aggregom-
try, VerifyNow P2Y12, and the Plateletworks assay (Helena
aboratories Corporation, Beaumont, Texas)—as best cor-
elating with the occurrence of a composite ischemic pri-
ary end point to 1 year (19). Interestingly, no correlation
etween platelet function studies and subsequent bleeding
vents could be discerned.
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o Clopidogrel Resistance
arious therapeutic algorithms have been offered (but re-
ain unproven) to ameliorate ischemic risk in patients
yporesponsive or resistant to clopidogrel, including:
) increasing clopidogrel dose (20); 2) switching to ticlopi-
ine (21); 3) the addition of CYP inducers to enhance
lopidogrel conversion (22); 4) the addition of cilostazol
23); 5) periprocedural platelet glycoprotein IIb/IIIa inhibi-
ion (24); and 6) novel P2Y12 receptor inhibitors such as
rasugrel, ticagrelor, and elinogrel (25–27). Although in-
reasing clopidogrel dose may accelerate the time course and
nhance the magnitude of subsequent platelet inhibition,
espite doses of up to 2,400 mg, an unpredictable approx-
mately 10% of subjects remain unresponsive (20). Similarly,
clopidogrel maintenance dose of 150 g/day will “convert”
ery few “nonresponders” to “responders” when a platelet
eactivity index by vasodilator-stimulated phosphoprotein
efinition of 50% (for response) is used (28). It has been
uggested that “tailored treatment” (with clopidogrel) is not
he ideal solution for clopidogrel resistance (29). Although
eriprocedural glycoprotein IIb/IIIa receptor blockade is
ffective in reducing ischemic events among patients resis-
ant to clopidogrel and/or aspirin (24), long-term outcomes
ave not been reported. Novel agents provide the greatest
romise. Prasugrel, a novel third-generation thienopyridine,
rovides more effective P2Y12 receptor inhibition, which
as been ascribed to more rapid, complete, and uniform
ctive metabolite generation (25). Importantly, neither the
harmacokinetic or pharmacodynamic response to prasugrel
or clinical outcomes appear to be adversely influenced by
YP2C19*2 carrier status (25). Clopidogrel-“resistant” pa-
ients are invariably responsive to ticagrelor, a novel cyclo-
entyl triazolopyrimidine nonthienopyridine reversible,
irect-acting P2Y12 receptor inhibitor. Ticagrelor therapy
ppears to provide superior inhibition of the P2Y12 receptor
n both clopidogrel responders and nonresponders and was
ssociated with a very low prevalence of HPR (26). Simi-
arly, elinogrel, a reversible, direct-acting P2Y12 receptor
nhibitor, significantly reduced aggregation and the portion
f subjects with HPR among clopidogrel nonresponders
27). Although Damani and Topol (1) suggest that an
nwillingness to perform widespread genotyping “de-
ies . . . patients state-of-the-art care,” they offer no guid-
nce as to an appropriate algorithm for response (for either
C19*2 heterozygotes or homozygotes) and provide no
evidence” as to the relative safety and efficacy of altering
herapy in this cohort of patients. This lack of direction
egarding appropriate therapy for poor metabolizers on the
asis of genotyping mirrors the statement made by the U.S.
ood and Drug Administration to “consider use of other
ntiplatelet medications or alternative dosing strategies for
clopidogrel].” Finally, an appropriate therapeutic response
o the presence of CYP2C19*17 (reduce clopidogrel dose)
as not been defined. pIn a recent study, the influence of both HPR and
enotyping on clinical outcomes in a percutaneous coronary
ntervention cohort was evaluated separately. Although
YP2C19*2 and HPR had comparatively high specificity
72% and 79%), each factor independently identified only
6% of patients with events. Interestingly, 75% of patients
ith events were identified when both risk factors were
ombined (30). The latter observation suggests that both
enotyping and ex vivo platelet function testing may be
ore predictive than either alone. This concept makes sense
iven that the CYP2C19 genotype is invariant and accounts
or a constant portion of clopidogrel response variability,
hile platelet function testing is an integrated measure of
any factors, both genetic and nongenetic, and is thus more
ynamic in an individual patient. While genotyping assays
re straightforward and highly accurate and reproducible,
oint-of-care platelet aggregation testing platforms are
omparatively less accurate because of technical factors.
Finally, we wish to clarify 3 additional points. First,
amani and Topol (1) mention that the relation of genetic
olymorphisms to alteration in clopidogrel active metabolite
evels was noted in various large-scale clinical investigations
nvolving patients (6,8,11,12,31), but active metabolite lev-
ls were analyzed only in healthy volunteers in the study by
ega et al. (8). Second, in the study by Shuldiner et al. (6),
n addition to stent thrombosis and cardiovascular death,
ther events, such as myocardial infarction, ischemic stroke,
nplanned target vessel revascularization, unplanned non–
arget vessel revascularization, hospitalization for coronary
schemia without revascularization, and death secondary
o any cardiovascular cause at 1-year follow-up, were also
ssessed. Third, the proposal by Damani and Topol (1) that
schemic events in the clopidogrel arm of the PLATO
Platelet Inhibition and Patient Outcomes) study may be
elated to the presence of resistance alleles is speculative and
remature, as the results of the genetic substudy of PLATO
re not yet available (32).
onclusions
ecent studies indicate that the CYP2C19 genotype is an
mportant predictor of the laboratory and clinical response
o clopidogrel. We share the enthusiasm of Damani and
opol (1) for the promise of genotyping to tailor antiplatelet
herapy. Commercially available CYP2C19 genetic testing
and soon point-of-care genetic testing) has now made it
ossible to use CYP2C19 genotype to “guide” antiplatelet
herapy. However, the safety and efficacy of altering therapy
n response to genotypic or phenotypic testing are entirely
nknown. While neither alone adequately describes the
lobal risk profile of an individual patient treated with
lopidogrel, point-of-care platelet function testing to iden-
ify HRP combined with CYP2C19 genetic testing may be
ore effective in identifying high-risk patients for alterna-
ive antiplatelet therapies than either alone. Ultimately,
rospective randomized clinical trials will be needed to test
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vidence base necessary for widespread adoption into clin-
cal practice.
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